TY - JOUR
T1 - Performance of non-traditional hyperglycemia biomarkers by chronic kidney disease status in older adults with diabetes
T2 - Results from the Atherosclerosis Risk in Communities Study
AU - Jung, Molly
AU - Warren, Bethany
AU - Grams, Morgan
AU - Kwong, Yuenting D.
AU - Shafi, Tariq
AU - Coresh, Josef
AU - Rebholz, Casey M.
AU - Selvin, Elizabeth
N1 - Funding Information:
The Atherosclerosis Risk in Communities (ARIC) Study is performed as a collaborative study supported by National Heart, Lung, and Blood Institute (NHLBI) contracts (HHSN268201700001I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I, and HHSN2682017000021). MJ and BW were supported by a grant from the National Institutes of Health (NIH)/NHLBI (T32 HL007024); TS was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant R03DK104012 and NHLBI grant R01HL132372-01. This research was supported by grants from the NIDDK (R01DK089174 and K24DK106414 to ES). CMR was supported by a grant from the NIDDK (K01DK107782). The authors thank the staff and participants of the ARIC Study for their important contributions. Reagents for the glycated albumin assays were donated by the Asahi Kasei Pharma Corporation. Reagents for the fructosamine assays were donated by Roche Diagnostics.
Funding Information:
The Atherosclerosis Risk in Communities (ARIC) Study is performed as a collaborative study supported by National Heart, Lung, and Blood Institute (NHLBI) contracts (HHSN268201700001I, HHSN26820170000 3I, HHSN268201700005I, HHSN268201700004I, and HHSN2682017000021). MJ and BW were supported by a grant from the National Institutes of Health (NIH)/ NHLBI (T32 HL007024); TS was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant R03DK104012 and NHLBI grant R01HL132372-01. This research was supported by grants from the NIDDK (R01DK089174 and K24DK106414 to ES). CMR was supported by a grant from the NIDDK (K01DK107782). The authors thank the staff and participants of the ARIC Study for their important contributions. Reagents for the glycated albumin assays were donated by the Asahi Kasei Pharma Corporation. Reagents for the fructosamine assays were donated by Roche Diagnostics.
Publisher Copyright:
© 2017 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd
PY - 2018/4
Y1 - 2018/4
N2 - Background: In people with chronic kidney disease (CKD), HbA1c may be a problematic measure of glycemic control. Glycated albumin and fructosamine have been proposed as better markers of hyperglycemia in CKD. In the present study we investigated associations of HbA1c, glycated albumin, and fructosamine with fasting glucose by CKD categories. Methods: A cross-sectional analysis was performed of 1665 Atherosclerosis Risk in Communities Study participants with diagnosed diabetes aged ≥65 years. Spearman's rank correlations (r) were compared and Deming regression was used to obtain root mean square errors (RMSEs) for the associations across CKD categories defined using estimated glomerular filtration rate and urine albumin:creatinine ratio. Results: Correlations of HbA1c, glycated albumin, and fructosamine with fasting glucose were lowest in people with severe CKD (HbA1c r = 0.52, RMSE = 0.91; glycated albumin r = 0.39, RMSE = 1.89; fructosamine r = 0.41, RMSE = 1.87) and very severe CKD (r = 0.48 and RMSE = 1.01 for HbA1c; r = 0.36 and RMSE = 2.14 for glycated albumin; r = 0.36 and RMSE = 2.22 for fructosamine). Associations of glycated albumin and fructosamine with HbA1c were relatively similar across CKD categories. Conclusions: In older adults with severe or very severe CKD, HbA1c, glycated albumin, and fructosamine were not highly correlated with fasting glucose. The results suggest there may be no particular advantage of glycated albumin or fructosamine over HbA1c for monitoring glycemic control in CKD.
AB - Background: In people with chronic kidney disease (CKD), HbA1c may be a problematic measure of glycemic control. Glycated albumin and fructosamine have been proposed as better markers of hyperglycemia in CKD. In the present study we investigated associations of HbA1c, glycated albumin, and fructosamine with fasting glucose by CKD categories. Methods: A cross-sectional analysis was performed of 1665 Atherosclerosis Risk in Communities Study participants with diagnosed diabetes aged ≥65 years. Spearman's rank correlations (r) were compared and Deming regression was used to obtain root mean square errors (RMSEs) for the associations across CKD categories defined using estimated glomerular filtration rate and urine albumin:creatinine ratio. Results: Correlations of HbA1c, glycated albumin, and fructosamine with fasting glucose were lowest in people with severe CKD (HbA1c r = 0.52, RMSE = 0.91; glycated albumin r = 0.39, RMSE = 1.89; fructosamine r = 0.41, RMSE = 1.87) and very severe CKD (r = 0.48 and RMSE = 1.01 for HbA1c; r = 0.36 and RMSE = 2.14 for glycated albumin; r = 0.36 and RMSE = 2.22 for fructosamine). Associations of glycated albumin and fructosamine with HbA1c were relatively similar across CKD categories. Conclusions: In older adults with severe or very severe CKD, HbA1c, glycated albumin, and fructosamine were not highly correlated with fasting glucose. The results suggest there may be no particular advantage of glycated albumin or fructosamine over HbA1c for monitoring glycemic control in CKD.
KW - biomarkers
KW - chronic kidney disease
KW - epidemiology
KW - older adults
UR - http://www.scopus.com/inward/record.url?scp=85038835653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038835653&partnerID=8YFLogxK
U2 - 10.1111/1753-0407.12618
DO - 10.1111/1753-0407.12618
M3 - Article
C2 - 29055090
AN - SCOPUS:85038835653
SN - 1753-0393
VL - 10
SP - 276
EP - 285
JO - Journal of Diabetes
JF - Journal of Diabetes
IS - 4
ER -